novartis

A Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-DFC413 and Safety and Imaging Properties of [68Ga]Ga-NNS309 in Patients With Solid Tumors

Description:

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients aged ≥ 18 years with solid tumors

Sponsor:

Novartis

Contacts:

Novartis Pharmaceuticals

novartis.email@novartis.com

1-888-669-6682

Isotope(s):
Target(s):
  • FAP

68Ga-NNS309

Isotope(s):
Target(s):
  • FAP

Patient Education


Patient Education Not Yet Provided

Publications


Publications Not Yet Provided

Locations


Israel 🇮🇱

Novartis Investigative Site - Israel

Israel

XCancer

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468